Search Tag: ECMO therapy
2024 19 Nov
Strategic Relationship: Agreement expands access to ECMO solutions for hospitals, health systems and patients in the U.S. nationwide. Wide Reach: 4,350+ Premier member hospitals and health systems in the U.S. can leverage pre-negotiated terms and pricing on the Novalung System for ECMO. Commitment to Quality Care: Reinforces company’s...Read more
2020 30 Apr
As the coronavirus spreads and infections with COVID-19 further increase throughout Europe, ECMO therapy turns out to be a necessary option for patients with severe courses. Xenios AG , a subsidiary of Fresenius Medical Care, provides ECMO consoles that can be used for the treatment of patients who develop severe pneumonia and ARDS with lung...Read more
2020 26 Feb
The US FDA (Food and Drug Administration) has granted 510(k) approval to Fresenius Medical Care North America and Xenios, a Fresenius Medical Care company, for long-term use of its Novalung system for patients with acute lung failure or acute cardiopulmonary failure. The FDA announced this on Friday evening. With class II approval, the Novalung...Read more